1. Home
  2. RNA vs ALGN Comparison

RNA vs ALGN Comparison

Compare RNA & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

HOLD

Current Price

$72.90

Market Cap

10.9B

Sector

Health Care

ML Signal

HOLD

Logo Align Technology Inc.

ALGN

Align Technology Inc.

HOLD

Current Price

$181.89

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNA
ALGN
Founded
2012
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
12.0B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
RNA
ALGN
Price
$72.90
$181.89
Analyst Decision
Buy
Buy
Analyst Count
20
11
Target Price
$69.26
$189.40
AVG Volume (30 Days)
2.1M
1.2M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
0.69
N/A
EPS
N/A
3.77
Revenue
$10,897,000.00
$387,126,000.00
Revenue This Year
$88.12
$5.85
Revenue Next Year
$18.11
$4.52
P/E Ratio
N/A
$50.40
Revenue Growth
13.99
23.95
52 Week Low
$25.28
$122.00
52 Week High
$73.06
$208.31

Technical Indicators

Market Signals
Indicator
RNA
ALGN
Relative Strength Index (RSI) 64.95 53.46
Support Level $70.42 $169.24
Resistance Level $73.04 $192.02
Average True Range (ATR) 0.21 8.17
MACD -0.05 -0.03
Stochastic Oscillator 60.24 60.69

Price Performance

Historical Comparison
RNA
ALGN

About RNA Avidity Biosciences Inc.

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: